Melanoma studies dominated both the Presidential Symposium and poster sessions at the European Society for Medical Oncology 2014 meeting. Practice changing trials endorsed the “precision medicine" theme of the meeting, held in Madrid, Spain, September 26-30, with studies demonstrating inhibiting two pathways was better than one and the first ever phase 3 trial data of a PD1 inhibitor.
Melbourne, Victoria, Australia.